q&a: how do oncologists approach compound egfr mutations? - targeted therapies in lung cancer 2023
Published 8 months ago • 27 plays • Length 3:46Download video MP4
Download video MP3
Similar videos
-
4:10
egfr mutations in advanced nsclc - targeted therapies in lung cancer 2023
-
3:02
resistance mechanisms in egfr nsclc treatment - targeted therapies in lung cancer 2023
-
5:13
q&a: how do i integrate palliative care services? - targeted therapies in lung cancer 2023
-
4:22
what is egfr in lung cancer? - 2022 program: targeted therapies forum
-
16:51
an introduction to advocacy - targeted therapies in lung cancer 2023
-
6:39
q&a: how do i handle side effects? - targeted therapies in lung cancer 2023
-
7:35
treatment for patients with egfr nsclc - leading developments & current questions in lung cancer
-
4:52
what is palliative care? - targeted therapies in lung cancer 2023
-
21:33
optimal ngs platforms, how to interpret - grace targeted therapies in lung cancer patient forum 2021
-
2:08
grace targeted therapies lung cancer 2021 - approved therapy for a cdkn2a secondary mutation?
-
1:09:58
breakout second stage 2023 targeted therapies in lung cancer forum on-demand
-
22:49
grace targeted therapies lung cancer 2021 - management of uncommon egfr mutations including exon 20
-
4:43
decreased cancer mortality: how treatments have improved - targeted therapies in lung cancer 2023
-
8:49
grace targeted therapies lung cancer 2021 - a role for chemo io in patients with egfr mutations?
-
5:31
biomarkers in nsclc - targeted therapies in lung cancer 2023
-
1:39
grace targeted therapies lung cancer 2021 - treatment after crizotinib in ros1 lung cancer
-
7:03
living with advanced cancer: handling uncertainty - targeted therapies in lung cancer 2023
-
2:36
the future of local therapy - targeted therapies in lung cancer 2023
-
1:15
gracecastuc-054_lung_wakelee: my approach to repeat biopsies for adv. nsclc with insufficient tissue